Cue Biopharma

52 articles with Cue Biopharma

• Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference

  11/23/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020. The pre-recorded presentation will be available to

• Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

  11/19/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes an

• Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

  11/17/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, provided a business update for the third quarter of 2020.

• Cue Biopharma to Present at Upcoming Investor Conferences in November 2020

  11/11/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference

• Cue Biopharma to Host Business Update Call and Webcast

  11/10/2020

  Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, November 17, 2020 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s  website . Members of the

• Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the SITC’s 35th Anniversary Annual Meeting

  11/9/2020

  Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the SITC’s 35th Anniversary Annual Meeting

• Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

  10/19/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 35 th Anniversary Annual Meeting (SITC 2020). Presentation Details: Title: Immuno-STATs: Leveraging protein engineering to expand and track antigen-sp

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Cue Biopharma Welcomes Tamar Howson to its Board of Directors

  9/17/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the appointment of Tamar Howson to its board of directors

• Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds

  9/15/2020

  Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the peer-reviewed publicat

• Cue Biopharma to Present at Upcoming Investor Conferences in September 2020

  9/3/2020

  Cue Biopharma, Inc. announced it will present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020 and the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 23, 2020.

• Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

  8/31/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the second quarter of 2020.

• Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit

  8/24/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™,

• Cue Biopharma to Host Business Update Call and Webcast - Aug 17, 2020

  8/17/2020

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced it will host a conference call and webcast to provide a business update on Monday, August 31, 2020 at 4:30 p.m. EDT.

• Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer

  7/28/2020

  CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of selecting a recommended Phase 2 dose

• Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily

  7/8/2020

  - Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engineer molecules for therapeutic immune modulation through Immuno-STAT and Neo-STAT platforms CAMBRIDGE, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceuti

• Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer

  6/15/2020

  Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 dose Dose-proportional increases in drug exposure combined with observations demonstrating pharmacodynamic biomarkers in peripheral blood and clinical data from scans bolsters confidence in potential for attractive therapeutic window CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (

• Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference

  5/28/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 9:00 a.m. EDT. Daniel Passeri, chief executive officer, will provide an overview of the Company’s Immuno-STAT™ (Selective Targ

• Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights

  5/19/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the first quarter 2020.

• Cue Biopharma to Present at AACR Virtual Annual Meeting

  5/18/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring pre-clinical data on CUE-102/A02 and CUE-102/A24, the company’s second and third drug candidates from the CUE-100 series at the American Association for Cancer Research (AACR) Virtual Annual Meeti